Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Hold" by Analysts

Shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) have been given an average rating of "Hold" by the seven analysts that are presently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $5.50.

DSGN has been the subject of a number of recent analyst reports. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $4.00 price target on shares of Design Therapeutics in a research note on Wednesday, March 20th. Wedbush reaffirmed a "neutral" rating and issued a $5.00 price target on shares of Design Therapeutics in a research note on Wednesday, March 20th.

Design Therapeutics Trading Down 2.1 %

Shares of DSGN stock traded down $0.08 on Friday, reaching $3.69. The company had a trading volume of 115,378 shares, compared to its average volume of 384,214. The stock has a market cap of $208.45 million, a PE ratio of -3.07 and a beta of 1.82. The company has a 50-day moving average of $3.02 and a 200-day moving average of $2.58. Design Therapeutics has a 12 month low of $1.94 and a 12 month high of $8.47.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last announced its quarterly earnings results on Tuesday, March 19th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.11. Sell-side analysts anticipate that Design Therapeutics will post -1.25 earnings per share for the current year.

Insider Buying and Selling

In other news, Director John P. Schmid purchased 17,809 shares of Design Therapeutics stock in a transaction on Monday, March 25th. The stock was purchased at an average price of $3.74 per share, with a total value of $66,605.66. Following the transaction, the director now directly owns 26,965 shares in the company, valued at approximately $100,849.10. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director John P. Schmid purchased 9,156 shares of Design Therapeutics stock in a transaction on Friday, March 22nd. The stock was purchased at an average price of $3.62 per share, with a total value of $33,144.72. Following the transaction, the director now directly owns 9,156 shares in the company, valued at approximately $33,144.72. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director John P. Schmid purchased 17,809 shares of Design Therapeutics stock in a transaction on Monday, March 25th. The shares were purchased at an average cost of $3.74 per share, with a total value of $66,605.66. Following the transaction, the director now owns 26,965 shares in the company, valued at $100,849.10. The disclosure for this purchase can be found here. 27.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Design Therapeutics

Large investors have recently made changes to their positions in the stock. Barclays PLC boosted its holdings in shares of Design Therapeutics by 353.1% in the 3rd quarter. Barclays PLC now owns 71,678 shares of the company's stock valued at $170,000 after buying an additional 55,858 shares during the last quarter. RTW Investments LP boosted its holdings in shares of Design Therapeutics by 60.8% in the 3rd quarter. RTW Investments LP now owns 2,512,986 shares of the company's stock valued at $5,931,000 after buying an additional 949,955 shares during the last quarter. Algert Global LLC boosted its holdings in shares of Design Therapeutics by 83.3% in the 3rd quarter. Algert Global LLC now owns 35,620 shares of the company's stock valued at $84,000 after buying an additional 16,190 shares during the last quarter. Jump Financial LLC boosted its holdings in shares of Design Therapeutics by 284.7% in the 3rd quarter. Jump Financial LLC now owns 46,700 shares of the company's stock valued at $110,000 after buying an additional 34,561 shares during the last quarter. Finally, Prescott Group Capital Management L.L.C. acquired a new stake in shares of Design Therapeutics in the 3rd quarter valued at approximately $425,000. Institutional investors and hedge funds own 56.64% of the company's stock.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.